Evidence map›Paper›PMID 40891712›Full record

ArticleCancer biomarkers : section A of Disease markers2025

PDCD2L overexpression represents an unfavorable prognostic marker and its inhibition shows promising therapeutic potential for gastric cancer.

Ding-Ping Sun, Chun-Chao Chang, Hsuan-Yi Huang, Nai-Weng Kang, You-Cheng Hseu, Yu-Feng Tian, Chia-Lang Fang, Kai-Yuan Lin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer biomarkers : section A of Disease markers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ding-Ping SunDepartment of Surgery, Chi Mei Medical Center, Tainan, Taiwan.
Chun-Chao ChangDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan.
Hsuan-Yi HuangDepartment of Surgery, Chi Mei Medical Center, Tainan, Taiwan.
Nai-Weng KangDepartment of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan.
You-Cheng HseuDepartment of Cosmeceutics, China Medical University, Taichung, Taiwan.
Yu-Feng TianDepartment of Surgery, Chi Mei Medical Center, Tainan, Taiwan.
Chia-Lang FangTMU Research Center for Digestive Medicine, Taipei Medical University, Taipei, Taiwan.
Kai-Yuan LinDepartment of Medical Research, Chi Mei Medical Center, Tainan, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BackgroundGastric cancer is the 4th most common and 3rd deadliest cancer worldwide. Research has shown that PDCD2-like (PDCD2L) is elevated in several tumors.ObjectiveTo explore the relationship between PDCD2L expression and gastric cancer prognosis and its function in gastric cancer.MethodsImmunohistochemical staining and immunoblotting were performed to examine the expression of PDCD2L. The effect of PDCD2L on gastric cancer cells were evaluated by a series of in vitro cellular function experiments and in vivo proliferation experiments.ResultsPDCD2L was found to be overexpressed in gastric cancer tissues compared to non-tumor tissues, and its higher levels were associated with worse prognosis. In vitro experiments showed that reducing PDCD2L expression in gastric cancer cells led to decreased proliferation, migration, and invasion, with a similar effect observed in animal models. Knockdown of PDCD2L also resulted in lower expression of cell cycle- and motility-related proteins, while upregulation of PDCD2L had the opposite effect. Additionally, NGS analysis revealed that PDCD2L knockdown reduced the expression of RFX1, a gene linked to cell proliferation and migration, suggesting that PDCD2L and RFX1 together promote cancer progression.ConclusionPDCD2L could serve as a biomarker for gastric cancer prognosis and a potential therapeutic target.

Indexed as

Apoptosis Regulatory ProteinsBiomarkers, TumorStomach NeoplasmsAnimalsCell Line, TumorCell MovementCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMaleMiceMiddle AgedPrognosisXenograft Model Antitumor AssaysApoptosis Regulatory ProteinsBiomarkers, TumorGastric cancerinvasionPDCD2Lprognosisproliferation

Identifiers

PMID40891712
PMCPMC13085924

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.